779 related articles for article (PubMed ID: 33909949)
1. Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration.
Ravi P; Pond GR; Diamantopoulos LN; Su C; Alva A; Jain RK; Skelton WP; Gupta S; Tward JD; Olson KM; Singh P; Grunewald CM; Niegisch G; Lee JL; Gallina A; Bandini M; Necchi A; Mossanen M; McGregor BA; Curran C; Grivas P; Sonpavde GP
BJU Int; 2021 Nov; 128(5):607-614. PubMed ID: 33909949
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
Zargar H; Shah JB; van Rhijn BW; Daneshmand S; Bivalacqua TJ; Spiess PE; Black PC; Kassouf W;
J Urol; 2018 Jun; 199(6):1452-1458. PubMed ID: 29329894
[TBL] [Abstract][Full Text] [Related]
3. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses.
Pfister C; Gravis G; Fléchon A; Soulié M; Guy L; Laguerre B; Mottet N; Joly F; Allory Y; Harter V; Culine S;
Eur Urol; 2021 Feb; 79(2):214-221. PubMed ID: 32868138
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California.
Fairey AS; Daneshmand S; Quinn D; Dorff T; Dorin R; Lieskovsky G; Schuckman A; Cai J; Miranda G; Skinner EC
Urol Oncol; 2013 Nov; 31(8):1737-43. PubMed ID: 23141776
[TBL] [Abstract][Full Text] [Related]
5. Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?
Pouessel D; Chevret S; Rolland F; Gravis G; Geoffrois L; Roubaud G; Terrisse S; Boyle H; Chevreau C; Dauba J; Moriceau G; Alexandre I; Deplanque G; Chapelle A; Vauleon E; Colau A; Audenet F; Grellety T; Culine S
Eur J Cancer; 2016 Feb; 54():69-74. PubMed ID: 26724422
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients.
Hamid ARAH; Ridwan FR; Parikesit D; Widia F; Mochtar CA; Umbas R
BMC Urol; 2020 Oct; 20(1):158. PubMed ID: 33054762
[TBL] [Abstract][Full Text] [Related]
7. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Zargar H; Espiritu PN; Fairey AS; Mertens LS; Dinney CP; Mir MC; Krabbe LM; Cookson MS; Jacobsen NE; Gandhi NM; Griffin J; Montgomery JS; Vasdev N; Yu EY; Youssef D; Xylinas E; Campain NJ; Kassouf W; Dall'Era MA; Seah JA; Ercole CE; Horenblas S; Sridhar SS; McGrath JS; Aning J; Shariat SF; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Garcia JA; Stephenson AJ; Shah JB; van Rhijn BW; Daneshmand S; Spiess PE; Black PC
Eur Urol; 2015 Feb; 67(2):241-9. PubMed ID: 25257030
[TBL] [Abstract][Full Text] [Related]
8. Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder.
Yeshchina O; Badalato GM; Wosnitzer MS; Hruby G; RoyChoudhury A; Benson MC; Petrylak DP; McKiernan JM
Urology; 2012 Feb; 79(2):384-90. PubMed ID: 22196406
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of neoadjuvant chemotherapy with four cycles of dose-dense MVAC followed by radical cystectomy in Korean patients with muscle-invasive or locally advanced urothelial carcinoma of bladder.
Park K; Lee HJ; Kim TU; Ryu H; Ki YK; Hong YJ; Nam JK
Asia Pac J Clin Oncol; 2023 Dec; 19(6):739-746. PubMed ID: 37461246
[TBL] [Abstract][Full Text] [Related]
10. Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscle-invasive bladder cancer treated with cisplatin-based neoadjuvant chemotherapy and radical cystectomy: a single-centre experience.
Boeri L; Soligo M; Frank I; Boorjian SA; Thompson RH; Tollefson M; Quevedo FJ; Cheville JC; Karnes RJ
BJU Int; 2019 Jun; 123(6):1011-1019. PubMed ID: 30623554
[TBL] [Abstract][Full Text] [Related]
11. Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine-cisplatin and high dose-intensity MVAC.
Lee Y; Kim YS; Hong B; Cho YM; Lee JL
J Cancer Res Clin Oncol; 2021 Nov; 147(11):3421-3429. PubMed ID: 33715088
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
Galsky MD; Pal SK; Chowdhury S; Harshman LC; Crabb SJ; Wong YN; Yu EY; Powles T; Moshier EL; Ladoire S; Hussain SA; Agarwal N; Vaishampayan UN; Recine F; Berthold D; Necchi A; Theodore C; Milowsky MI; Bellmunt J; Rosenberg JE;
Cancer; 2015 Aug; 121(15):2586-93. PubMed ID: 25872978
[TBL] [Abstract][Full Text] [Related]
13. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.
Kitamura H; Tsukamoto T; Shibata T; Masumori N; Fujimoto H; Hirao Y; Fujimoto K; Kitamura Y; Tomita Y; Tobisu K; Niwakawa M; Naito S; Eto M; Kakehi Y;
Ann Oncol; 2014 Jun; 25(6):1192-8. PubMed ID: 24669010
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Cisplatin-based Chemotherapy in Nonmetastatic Muscle-invasive Bladder Cancer: A Systematic Review and Pooled Meta-analysis to Determine the Preferred Regimen.
Eule CJ; Warren A; Molina Kuna E; Callihan EB; Kim SP; Flaig TW
Urology; 2024 Jun; 188():118-124. PubMed ID: 38685388
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.
Choueiri TK; Jacobus S; Bellmunt J; Qu A; Appleman LJ; Tretter C; Bubley GJ; Stack EC; Signoretti S; Walsh M; Steele G; Hirsch M; Sweeney CJ; Taplin ME; Kibel AS; Krajewski KM; Kantoff PW; Ross RW; Rosenberg JE
J Clin Oncol; 2014 Jun; 32(18):1889-94. PubMed ID: 24821883
[TBL] [Abstract][Full Text] [Related]
16. Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series.
Weight CJ; Garcia JA; Hansel DE; Fergany AF; Campbell SC; Gong MC; Jones JS; Klein EA; Dreicer R; Stephenson AJ
Cancer; 2009 Feb; 115(4):792-9. PubMed ID: 19127557
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin.
van de Putte EE; Mertens LS; Meijer RP; van der Heijden MS; Bex A; van der Poel HG; Kerst JM; Bergman AM; Horenblas S; van Rhijn BW
World J Urol; 2016 Feb; 34(2):157-62. PubMed ID: 26184106
[TBL] [Abstract][Full Text] [Related]
18. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
Pfister C; Gravis G; Flechon A; Chevreau C; Mahammedi H; Laguerre B; Guillot A; Joly F; Soulie M; Allory Y; Harter V; Culine S;
Lancet Oncol; 2024 Feb; 25(2):255-264. PubMed ID: 38142702
[TBL] [Abstract][Full Text] [Related]
19. Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle-invasive bladder cancer.
Pal SK; Ruel NH; Wilson TG; Yuh BE
Clin Genitourin Cancer; 2012 Dec; 10(4):246-50. PubMed ID: 22981208
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis.
Yin M; Joshi M; Meijer RP; Glantz M; Holder S; Harvey HA; Kaag M; Fransen van de Putte EE; Horenblas S; Drabick JJ
Oncologist; 2016 Jun; 21(6):708-15. PubMed ID: 27053504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
